ORBIMED ADVISORS LLC
Q3 2020 13F-HR Holdings
Net value change ($000)
+853,190
(12.0%)
New positions
28
Sold out positions
19
Turnover %
21.3%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q2 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| PRLD | 469,874 | NEW |
| PMVP | 260,230 | NEW |
| Acutus Medical, Inc. | 163,243 | NEW |
| ACET | 79,764 | NEW |
| Horizon Therapeutics Public Ltd Co | 74,322 | 46.6% |
| Mirati Therapeutics, Inc. | 67,516 | 44.7% |
| Turning Point Therapeutics, Inc. | 62,511 | 35.3% |
| CALC | 56,888 | NEW |
| XLRN | 55,491 | 456.8% |
| ELDN | 52,976 | 3631.0% |
Top Reduces (Value $000, Stocks/ETFs)
| Tricida, Inc. | -177,095 | -67.0% |
| ASND | -117,818 | -51.0% |
| ALEC | -117,326 | -80.3% |
| PASG | -99,012 | -52.0% |
| CI | -82,510 | -100.0% |
| Prevail Therapeutics Inc. | -65,242 | -31.7% |
| GKOS | -46,527 | -100.0% |
| BELLUS Health Inc. | -41,273 | -77.9% |
| NXTC | -34,267 | -59.0% |
| SLQT | -31,789 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
42,532
(0.5% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|